Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...